John Lloyd Clinical Excellence Fund Project Grants - Previous recipients
2023 John Lloyd Clinical Excellence Project Grant recipients
The members of the AHCDO Executive Committee are pleased to announce that the successful applications for 2023 - 2024 is
Dr Brian Grainger (VIC - Alfred Hospital) for the project titled ‘T cell dysfunction and clinical outcomes in Acquired Haemophilia A: A prospective cohort study’.
Dr Jessica Wong (WA - Perth Children’s Hospital) for the project titled ‘'A pilot study investigating the immunogenicity and safety of subcutaneous versus intramuscular influenza immunisations in people with haemophilia A and B'.
2022 John Lloyd Clinical Excellence Project Grant recipient
The Amembers of the AHCDO Executive Committee are pleased to announce that the successful application for 2022 - 2023 is
Dr Radha Ramanan for the project titled ‘Phenotypic characterisation and molecular profiling of congenital fibrinogen disorders: the Australian experience’.
Congenital fibrinogen disorders are rare disorders affecting one of the major clotting proteins of the blood, fibrinogen. These disorders are inherited which means these patients are born with the problem. This disorder causes different problems in different patients, for example, one person may experience blood clots while another may have problems with bleeding, while someone else again may have no noticeable problems at all. Given the rarity of this disorder, we are still trying to understand why some patients behave differently to others. Some of this difference may relate to the various gene mutations that can be seen with this condition. Genes are the genetic material which code for all the proteins in the body, including the fibrinogen clotting factor. This project will look closely at the types of gene mutations seen in various patients with a fibrinogen disorder by genetic testing. We will also record the types of bleeding or clotting problems these patients have experienced over their lifetime, and if any of those problems arose during pregnancy or surgeries. We will assess types of treatment these patients have received in these different settings.
Significance: This project aims to provide an analysis of real-world data concerning the CFD cohort across Australia. The results obtained will inform how successful current therapeutic approaches are in the prevention of bleeding/thrombotic events. It will also broaden our understanding of the genotype-phenotype correlation present within this disorder and guide whether molecular typing at diagnosis may help us better characterise the clinical phenotype, navigate future treatment decisions, particularly regarding prophylaxis, and ascribe inheritance risk in this complex cohort of patients.
Dr Radha Ramanan is a Haematology Fellow at Alfred Health and is also undertaking a PhD at Monash University, having completed her advanced training in clinical and laboratory haematology in 2021 at Alfred Health. Radha is also the current AHCDO Research Fellow. Radha has an interest in bleeding disorders and molecular pathology and seeks to broaden our understanding of these fields through research funded by AHCDO.
Caroline Dix (The Alfred, Vic): Thrombin generation assays– can they be used to assess the safety of anticoagulants and antiplatelet agents in people with haemophilia who develop cardiovascular disease?
Meredith Wiggins (Sydney Children's Hospital, NSW): Off-target effects of Emicizumab in children
Pat Metherom (Perth Blood Institute, WA): Is the Bleeding phenotype in low vWF patients caused by aberrant platelet receptor signalling and/or polymorphisms?
Yvonne Brennan (Westmead Hospital, NSW): Can the overall haemostatic potential (OHP) assay predict bleeding in patients with factor XI deficiency?
Jim Tiao (WACTH, WA):Therapeutic Antisense Oligonucleotides Targeting F8 mRNA Splicing as a Novel Therapy for Haemophilia A
Sally Campbell (Alfred Health, Vic): Evaluating the invitro effect of antithrombin (AT) inhibition on thrombin generation in patients with Factor V deficiency with AT-antibodies
Geoff Kershaw (RPAH, NSW): A Field Study of the Measurement of Recombinant and Extended Half-Life Factor IX Products by Chromogenic and One-stage assays
Stephanie P'ng (FSH, WA): Assessment of Immune Function Before and After Treatment with Recombinant Factor VIII fused with Fc Fragments
Ross Baker (WACTH, WA): Development of specific exon 14 targeting antisense oligonucleotides designed to modify F8 mRNA splicing as a potential treatment for Haemophilia A
Huyen Tran (Alfred health, Vic): Exploring the possible effects of tranexamic acid administration on the immune and inflammatory responses in patients with haemophilia
Ross Baker (WACTH, WA): A pilot study investigating the utility of morpholino technology to restore FVIII function in a select group of Haemophilia A patients
Simon Brown (LCCH, Qld): The Feasibility, efficacy and acceptability of using telehealth to provide multi-disciplinary assessment and advice for children with inherited bleeding disorders.
Julie Curtin (CHW, NSW): Implementation of a short message service (SMS) to document bleeding episodes in children with haemophilia and related bleeding disorders in a paediatric haemophilia treatment centre
Simon McRae (RAH, SA): Evaluation of the acceptability of pharmacokinetic based dosing in patients with severe haemophilia in an Australian setting
Paul Harnett: An evaluation of the efficacy of a parenting program to improve adherence to the prophylactic treatment of their children’s haemophilia
Esben Strodl: Using new media to improve adherence to medical regimes among adolescents with haemophilia
Rob Herbert: Development of a Bleeds Risk Calculator